Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 2180-2189

  Pandha, Hardev S ^a   Martin, Lesley Ann ^a   Rigg, Anne ^a   Hurst, Helen C ^a   Stamp, Gordon W H ^a   Sikora, Karol ^a   Lemoine, Nicholas R ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCYTOSINE; FLUOROURACIL; PRODRUG;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; FEMALE; GENE OVEREXPRESSION; GENE THERAPY; HUMAN; INTRATUMORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUICIDE GENE; TUMOR REGRESSION;

EID: 0033022611     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.2180     Document Type: Article

References (28)

1. Huber BE, Austin EA, Good SS, et al: In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 53:4619-4626, 1993
2. Mullen CA, Coale MM, Lowe R, et al: Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res 54:1503-1506, 1994
3. Lovekin C, Ellis IO, Locker A, et al: c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 63:439-443, 1991
4. Gusterson BA, Gelber RD, Goldhirsch A, et al: Prognostic importance of c-erbB-2 expression in breast cancer: International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-1056, 1992
5. Borg A, Tandon AK, Sigurdsson H, et al: HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50:4332-4337, 1990
6. Richner J, Gerber HA, Locher GW, et al: c-erbB-2 protein expression in node negative breast cancer. Ann Oncol 1:263-268, 1990
7. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
8. Gullick WJ, Love SB, Wright C, et al: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63:434-438, 1991
9. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
10. Borg A, Baldetorp B, Ferno M, et al: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81:137-144, 1994
11. Tetu B, Brisson J, Sigurdsson H, et al: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. Cancer 73:2359-2365, 1994
12. Harris JD, Gutierrez AA, Hurst HC, et al: Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1:170-175, 1994
13. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
14. Hollywood DP, Hurst HC: A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J 12:2369-2375, 1993
15. Haack K, Moebius U, Knebel Doeberitz MV, et al: Detection of cytosine deaminase in genetically modified tumor cells by specific antibodies. Hum Gene Ther 8:1395-1401, 1997
16. Senior PV, Byrne S, Brammar WJ, et al: Expression of the IGF-II/mannose-6-phosphate receptor mRNA and protein in the developing rat. Development 109:67-73, 1990
17. Andersen L, Kilstrup M, Neuhard J: Pyrimidine, purine and nitrogen control of cytosine deaminase synthesis in Escherichia coli K 12. Involvement of the glnLG and purR genes in the regulation of codA expression. Arch Microbiol 152:115-118, 1989
18. Caruso M, Panis Y, Gagandeep S, et al: Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A 90:7024-7028, 1993
19. Barba D, Hardin J, Sadelain M, et al: Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A 91:4348-4352, 1994
20. Vile RG, Nelson JA, Castleden S, et al: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54:6228-6234, 1994
21. Consalvo M, Mullen CA, Modesti A, et al: 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 154:5302-5312, 1995
22. Freeman SM, Ramesh R, Marrogi AJ: Immune system in suicide-gene therapy. Lancet 349:2-3, 1997
23. Vile RG, Miller N, Chernajovsky Y, et al: A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther 1:307-316, 1994
24. Richards CA, Huber BE: Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of transgene expression. Hum Gene Ther 4:143-150, 1993
25. Ring CJ, Harris JD, Hurst HC, et al: Suicide gene expression induced in tumour cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBR2 promoter. Gene Ther 3:1094-1103, 1996
26. Ram Z, Culver KW, Oshiro EM, et al: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3:1354-1361, 1997
27. Ring CJ, Blouin P, Martin LA, et al: Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme. Gene Ther 4:1045-1052, 1997
28. Rogulski KR, Kim JH, Kim SH, et al: Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 8:73-85, 1997